Circulating tumor DNA as a biomarker for the prediction of minimal residual disease and the individualization of adjuvant therapy in colorectal cancer - a review of current evidence and perspectives
GastroenterologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
- Publicado em
- 1 jan 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Circulating tumor DNA as a biomarker for the prediction of minimal residual disease and the individualization of adjuvant therapy in colorectal cancer - a review of current evidence and perspectives
A Pirshtuk, T Buchler, V Vymetálková
Descritores MeSH
- Circulating Tumor DNA
- Biomarkers, Tumor
- Colorectal Neoplasms
- Prognosis
- Chemotherapy, Adjuvant
- Neoplasm, Residual
- Humans
- Neoplasm Recurrence, Local
Veja também
Estudos relacionados
- Terapia Adjuvante Guiada por ctDNA no Câncer Colorectal Ressecado: Revisão Sistemática e Meta-análise da Validade Prognóstica versus Utilidade Tratamento-Decisão
- Prognostic Value of Circulating Tumor DNA for Recurrence Risk in Stage III Colorectal Cancer: A Systematic Review and Meta-Analysis
- Circulating Tumor DNA as a Real-Time Biomarker for Minimal Residual Disease and Recurrence Prediction in Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis
- Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis